Company Name: |
Changzhou Hopschain Chemical Co.,Ltd.
|
Tel: |
0519-85528066 13775048983 |
Email: |
sales@hopschem.com |
Products Intro: |
Product Name:BCN-exo-PEG3-NH2 CAS:1841134-72-2 Purity:95% Package:1mg;10mg;100mg;1g
|
5,?8,?11-?Trioxa-?2-?azatridecanoic acid, 13-?amino-?, (1α,?8α,?9α)?-?bicyclo[6.1.0]?non-?4-?yn-?9-?ylmethyl ester manufacturers
- exo BCN-PEG3-amine
-
- $0.00 / 50mg
-
2024-03-20
- CAS:1841134-72-2
- Min. Order: 50mg
- Purity: >95.00%
- Supply Ability: 250mg
|
| 5,?8,?11-?Trioxa-?2-?azatridecanoic acid, 13-?amino-?, (1α,?8α,?9α)?-?bicyclo[6.1.0]?non-?4-?yn-?9-?ylmethyl ester Basic information |
Product Name: | 5,?8,?11-?Trioxa-?2-?azatridecanoic acid, 13-?amino-?, (1α,?8α,?9α)?-?bicyclo[6.1.0]?non-?4-?yn-?9-?ylmethyl ester | Synonyms: | BCN-PEG3-AMINE (EXO);exo BCN-PEG3-NH2;BCN-exo-PEG3-NH2;exo BCN-PEG3-amine;5,8,11-Trioxa-2-azatridecanoic acid, 13-amino-, (1α,8α,9α)-bicyclo[6.1.0]non-4-yn-9-ylmethyl ester | CAS: | 1841134-72-2 | MF: | C19H32N2O5 | MW: | 368.47 | EINECS: | | Product Categories: | SiChem | Mol File: | 1841134-72-2.mol | ![5,?8,?11-?Trioxa-?2-?azatridecanoic acid, 13-?amino-?, (1α,?8α,?9α)?-?bicyclo[6.1.0]?non-?4-?yn-?9-?ylmethyl ester Structure](CAS/20211123/GIF/1841134-72-2.gif) |
| 5,?8,?11-?Trioxa-?2-?azatridecanoic acid, 13-?amino-?, (1α,?8α,?9α)?-?bicyclo[6.1.0]?non-?4-?yn-?9-?ylmethyl ester Chemical Properties |
Boiling point | 519.6±40.0 °C(Predicted) | density | 1.14±0.1 g/cm3(Predicted) | pka | 12.05±0.46(Predicted) |
| 5,?8,?11-?Trioxa-?2-?azatridecanoic acid, 13-?amino-?, (1α,?8α,?9α)?-?bicyclo[6.1.0]?non-?4-?yn-?9-?ylmethyl ester Usage And Synthesis |
Biological Activity | BCN-?exo-?PEG3-?NH2 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1].
PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1]. | References | [1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562 |
| 5,?8,?11-?Trioxa-?2-?azatridecanoic acid, 13-?amino-?, (1α,?8α,?9α)?-?bicyclo[6.1.0]?non-?4-?yn-?9-?ylmethyl ester Preparation Products And Raw materials |
|